Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

TA127 Multiple sclerosis - natalizumab: review decision - July 2013 information

TA127 Multiple sclerosis - natalizumab: Appendix A - Decision paper presented to the Institute's Guidance Executive

TA127 Multiple sclerosis - natalizumab: Appendix A - Decision paper presented to the Institute's Guidance Executive (PDF 391 KB)

TA127 Multiple sclerosis - natalizumab: review poposal - May 2013 information

Multiple sclerosis - natalizumab: Appendix A - provisional matrix of stakeholders

Multiple sclerosis - natalizumab: Appendix A - provisional matrix of stakeholders (PDF 39 KB)

Multiple sclerosis - natalizumab: Appendix B - proposal paper presented to the Institute's Guidance Executive

Multiple sclerosis - natalizumab: Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 750 KB)

Review Decision - December 2010 information

Appendix A: decision paper considered by the Institute's Guidance Executive

Appendix A: decision paper considered by the Institute's Guidance Executive (PDF 45 KB)

Review proposal - October 2010 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 30 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 138 KB)

NICE recommends natalizumab for the treatment of multiple sclerosis information

NICE recommends natalizumab for the treatment of multiple sclerosis (PDF 34 KB)

TA127 Multiple sclerosis - natalizumab: distribution list

Multiple sclerosis - natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis: Final appraisal determination

Consultee and commentator comments on the ACD

Biogen Idec UK

Biogen Idec UK (PDF 524 KB)

Biogen Idec UK - email

Biogen Idec UK - email (PDF 111 KB)

Association of British Neurologists

Association of British Neurologists (PDF 281 KB)

Multiple Sclerosis Trust

Multiple Sclerosis Trust (PDF 60 KB)

Royal College of Physicians

Royal College of Physicians (PDF 39 KB)

Royal College of Nursing

Royal College of Nursing (PDF 24 KB)

Department of Health

Department of Health (PDF 8.8 KB)

Oldham PCT

Oldham PCT (PDF 26 KB)

Department of Health Social Services and Public Safety for Northern Ireland

Department of Health Social Services and Public Safety for Northern Ireland (PDF 19 KB)

Multiple Sclerosis Group, University of Bristol

Multiple Sclerosis Group, University of Bristol (PDF 25 KB)

Merck Serono

Merck Serono (PDF 28 KB)

Expert comments on the ACD

Caroline Haynes, patient expert, nominated by Multiple Sclerosis Trust

Caroline Haynes, patient expert, nominated by Multiple Sclerosis Trust (PDF 20 KB)

Mark Priest, patient expert, nominated by Multiple Sclerosis Trust

Mark Priest, patient expert, nominated by Multiple Sclerosis Trust (PDF 34 KB)

Multiple sclerosis - natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis: Final appraisal determination

Multiple sclerosis - natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis: Final appraisal determination (PDF 72 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Multiple sclerosis - natalizumab: Evaluation report

Multiple sclerosis - natalizumab: Evaluation report - Pre-meeting briefing

Multiple sclerosis - natalizumab: Evaluation report - Pre-meeting briefing (PDF 96 KB)

Multiple sclerosis - natalizumab: Evaluation report - Erratum to the Pre-meeting briefing

Multiple sclerosis - natalizumab: Evaluation report - Erratum to the Pre-meeting briefing (PDF 26 KB)

Multiple sclerosis - natalizumab: Evaluation report - Evidence Review Group Report

Multiple sclerosis - natalizumab: Evaluation report - Evidence Review Group Report (PDF 517 KB)

Multiple sclerosis - natalizumab: Evaluation report - Manufacturer response to clarification letter

Multiple sclerosis - natalizumab: Evaluation report - Manufacturer response to clarification letter (PDF 154 KB)

Multiple sclerosis - natalizumab: Evaluation report Manufacturer Questionnaire

Multiple sclerosis - natalizumab: Evaluation report Manufacturer Questionnaire (PDF 437 KB)

Multiple sclerosis - natalizumab: Evaluation report - NICE Clarification letter

Multiple sclerosis - natalizumab: Evaluation report - NICE Clarification letter (PDF 36 KB)

Multiple sclerosis - natalizumab: Manufacturer submissions

Multiple sclerosis - natalizumab: Manufacturer submissions - Biogen Idec UK and Elan Pharma International Ltd - joint development agreement (confidential information removed)

Multiple sclerosis - natalizumab: Manufacturer submissions - Biogen Idec UK and Elan Pharma International Ltd - joint development agreement (confidential information removed) (PDF 1.85 MB)

Multiple sclerosis - natalizumab: Manufacturer submissions - Biogen Idec UK and Elan Pharma International Ltd addendum- joint development agreement (confidential information removed)

Multiple sclerosis - natalizumab: Manufacturer submissions - Biogen Idec UK and Elan Pharma International Ltd addendum- joint development agreement (confidential information removed) (PDF 672 KB)

Multiple sclerosis - natalizumab: Non-Manufacturer submissions

Multiple sclerosis - natalizumab: Non-Manufacturer submissions - Association of British Neurologists

Multiple sclerosis - natalizumab: Non-Manufacturer submissions - Association of British Neurologists (PDF 42 KB)

Multiple sclerosis - natalizumab: Non-Manufacturer submissions - Multiple Sclerosis Society

Multiple sclerosis - natalizumab: Non-Manufacturer submissions - Multiple Sclerosis Society (PDF 94 KB)

Multiple sclerosis - natalizumab: Non-Manufacturer submissions - Multiple Sclerosis Trust

Multiple sclerosis - natalizumab: Non-Manufacturer submissions - Multiple Sclerosis Trust (PDF 48 KB)

Multiple sclerosis - natalizumab: Non-Manufacturer submissions - Primary Care Neurology Society & Leeds Primary Care Trust (joint statement)

Multiple sclerosis - natalizumab: Non-Manufacturer submissions - Primary Care Neurology Society & Leeds Primary Care Trust (joint statement) (PDF 42 KB)

Multiple sclerosis - natalizumab: Non-Manufacturer submissions - Royal College of Nursing

Multiple sclerosis - natalizumab: Non-Manufacturer submissions - Royal College of Nursing (PDF 49 KB)

Multiple sclerosis - natalizumab: Non-Manufacturer submissions - Royal College of Physicians ofEdinburgh

Multiple sclerosis - natalizumab - final scope

Multiple sclerosis - natalizumab - draft scope

Multiple sclerosis - natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis: Final appraisal determination  information

Mark Priest, patient expert, nominated by Multiple Sclerosis Trust

Mark Priest, patient expert, nominated by Multiple Sclerosis Trust (PDF 34 KB)

Caroline Haynes, patient expert, nominated by Multiple Sclerosis Trust

Caroline Haynes, patient expert, nominated by Multiple Sclerosis Trust (PDF 20 KB)

Merck Serono

Merck Serono (PDF 28 KB)

Multiple Sclerosis Group, University of Bristol

Multiple Sclerosis Group, University of Bristol (PDF 25 KB)

Department of Health Social Services and Public Safety for Northern Ireland

Department of Health Social Services and Public Safety for Northern Ireland (PDF 19 KB)

Oldham PCT

Oldham PCT (PDF 26 KB)

Department of Health

Department of Health (PDF 8.8 KB)

Royal College of Nursing

Royal College of Nursing (PDF 24 KB)

Royal College of Physicians

Royal College of Physicians (PDF 39 KB)

Multiple Sclerosis Trust

Multiple Sclerosis Trust (PDF 60 KB)

Association of British Neurologists

Association of British Neurologists (PDF 281 KB)

Biogen Idec UK - email

Biogen Idec UK - email (PDF 111 KB)

Biogen Idec UK

Biogen Idec UK (PDF 594 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 264 KB)

Multiple sclerosis - natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis: Final appraisal determination